Revinty Ellipta 92/22 μg, 184/22 μg Inhalation powder, pre-dispensed.
PDF Leaflet Revision Date: 22 May 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Maintenance treatment of asthma and COPD.
Dosage (summary)
One inhalation of 100/25 u03bcg or 200/25 u03bcg once daily for adults and adolescents 12 years and older.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety during pregnancy and lactation not established.
Key Drug Interactions
- Beta-blockers may cause bronchospasms.
- CYP3A4 inhibitors may increase systemic exposure.
Contraindications
- Severe milk-protein allergy
- Hypersensitivity to fluticasone furoate or vilanterol
Common side effects
- Pneumonia
- Headache
- Upper respiratory tract infection
- Bronchitis
- Candidiasis
Counselling Points
- Rinse mouth after use.
- Use regularly even when asymptomatic.
- Seek medical advice if symptoms worsen.
Serious warnings
- Not for acute asthma or COPD exacerbations.
- Paradoxical bronchospasm may occur.
- Increased risk of pneumonia in COPD patients.
Important Disclaimer
The Revinty Ellipta 92/22 μg, 184/22 μg Inhalation powder, pre-dispensed. professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
